Clinical trials: Cancer of Bladder
Muscle Invasive Bladder Cancer
A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
This research study is studying a new anti-cancer drug durvalumab (MEDI4736) with or without another new anti-cancer drug Oleclumab (MEDI9447) before surgery for bladder cancer.
- Trial name
- NCT03773666
- Testing
- Durvalumab, Oleclumab
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
This phase I/Ib trial seeks to find out the best dose, possible benefits and/or side effects of cabozantinib in combination with enfortumab vedotin in treating urothelial cancer that has spread to nearby tissues and lymph nodes…
- Conditions
- Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
- Trial name
- NCT04878029
- Testing
- Cabozantinib S-malate, Enfortumab Vedotin, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Emory University
Bladder Cancer
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
In this study, participants with high risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) therapy and who are considered ineligible for or have refused to undergo radical cystectomy…
- Trial name
- NCT02625961
- Testing
- Pembrolizumab, Pembrolizumab/vibostolimab coformulation, Favezelimab/pembrolizumab coformulation
- Volunteers
- 296 people
- Sponsor
- Merck Sharp & Dohme LLC
Succesful Obturator Nerve Block, Bladder Tumor
Comparison of Obturator Nerve Block With Ultrasound Guidance and Anatomical Signs
Comparison of the obturator nerve block in patients undergoing transurethral resection due to bladder tumor, technically using ultrasound guided or blinded with anatomical signs.
- Conditions
- Succesful Obturator Nerve Block, Bladder Tumor, Bleeding
- Trial name
- NCT04638569
- Testing
- obturator nerve block
- Where
- Turkey (Türkiye)
- Volunteers
- 116 people
- Sponsor
- Muğla Sıtkı Koçman University
Bladder Cancer
Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma
In order to explore the safety and antitumor efficacy of different doses of CDK4/6 inhibitor Palbociclib in combination with the Tislelizumab in platinum-refractory cT2-4aN0M0 bladder urothelial carcinoma, a phase Ib/II study was…
- Trial name
- NCT06364956
- Testing
- Tislelizumab combined with two predefined dose groups of palbociclib, RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial.
- Where
- 8 sites in China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Neoplasms, Solid Tumors
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available…
- Conditions
- Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer
- Trial name
- NCT02091141
- Testing
- Trastuzumab, Pertuzumab, Erlotinib
- Where
- 60 sites in United States
- Volunteers
- 673 people
- Sponsor
- Genentech, Inc.
Recurrent Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Trial name
- NCT01118351
- Testing
- sunitinib malate, immunohistochemistry staining method, TdT-mediated dUTP nick end labeling assay
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer, Bladder Cancer
Assessing Financial Toxicity Using the PROFFIT Questionnaire in Patients Treated With Mini-invasive Approach for Urological Malignancies.
Patients previously treated with robotic surgery for urological cancers such as prostate, bladder and kidney cancer will be enrolled, in particular patients operated in the last twelve months will be included after signing the…
- Conditions
- Prostate Cancer, Bladder Cancer, Kidney Cancer
- Trial name
- NCT06955910
- Testing
- questionnaires
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Urinary Bladder Neoplasms, Urologic Neoplasms
Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients
The purpose of this study is to evaluate the clinical response of the tumors within the bladder of recurrent NMIBC patients to Mitomycin-C embedded in UroGen Pharma's (known at that time as TheraCoat Ltd.) TC-3 Sterile Hydrogel…
- Conditions
- Urinary Bladder Neoplasms, Urologic Neoplasms, Neoplasms, Urinary Bladder Diseases
- Trial name
- NCT02891460
- Testing
- 40 mg MMC in 40 mL TC-3., 80 mg MMC in 40 mL TC-3.
- Where
- India
- Volunteers
- 18 people
- Sponsor
- UroGen Pharma Ltd.
Pain, Postoperative
Perioperative Analgesic Efficiency of Quadratus Lumborum Block vs Epidural in Radical Cystectomy
This study is performed to measure the perioperative analgesic efficiency of bilateral quadratus lumborum block versus epidural analgesia in bladder cancer patients undergoing radical cystectomy
- Trial name
- NCT04133051
- Testing
- Quadratus Lumborum Block Using Bupivacaine 0.2%, Epidural Analgesia Using Bupivacaine 0.25%
- Where
- Egypt
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute, Egypt
Sarcopenia, Bladder Cancer
SArcopenia, Mobility, PHYsical Activity and Post-operative Risk of Bladder Carcinoma in the Elderly
Sarcopenia is associated with lower prognosis in solid tumors, but this has not been studied in bladder carcinoma requiring cystectomy.
- Trial name
- SAMPHYR (NCT03362801)
- Testing
- sarcopenia and mobility measurement
- Where
- 3 sites in France
- Volunteers
- 69 people
- Sponsor
- University Hospital, Caen
Bladder Cancer, Skin Cancers
A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies
We hypothesize that all human malignancies harbour a subpopulation of tumor initiating cells/cancer stem cells (CSCs) that drives tumor development and potentially recurrence or metastasis of the disease.
- Conditions
- Bladder Cancer, Skin Cancers, Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)
- Trial name
- NCT01060319
- Where
- United States
- Sponsor
- Stanford University
Metastatic Urothelial Carcinoma
A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)
Platinum-based chemotherapy remains the standard of care for advanced/metastatic unresectable bladder cancer. The JAVELIN Bladder 100 and HCRN GU14-182 trials showed that maintenance immune checkpoint inhibition(ICI) for those…
- Trial name
- CARMA (NCT06050954)
- Testing
- Pembrolizumab (200mg), Pembrolizumab (400mg), Monitoring
- Sponsor
- Fox Chase Cancer Center
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Ureter Cancer, Urethral Cancer
- Trial name
- NCT01191892
- Testing
- carboplatin, gemcitabine hydrochloride, vandetanib
- Where
- 21 sites in United Kingdom
- Volunteers
- 82 people
- Sponsor
- Cardiff University
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics
Non-muscle Invasive Bladder Cancer
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
The purpose of this study is to test the safety of the study drug 2141-V11 in people whose NMIBC did not respond to standard treatment, and who will not have the standard surgical procedure to remove the bladder.
- Trial name
- NCT05126472
- Testing
- anti-CD40 antibody 2141-V11, Intravesical Gemcitabine, Intravesical Gemcitabine with anti-CD40 antibody 2141-V11
- Where
- 7 sites in United States
- Volunteers
- 115 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Urothelial Carcinoma, Bladder Cancer
Bio Clinical Collection of Urothelial Carcinoma
The goal of this study is to collect tumor samples, urines, stool and blood from patients with urothelial carcinoma. These samples will be stored in a secure and confidential laboratory of the Toulouse University Hospital.
- Trial name
- MicroBlad (NCT04970472)
- Testing
- collection of blood, urines, stool and tumor samples
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Toulouse
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as FR901228 (depsipeptide), work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00087295
- Testing
- Depsipeptide
- Volunteers
- 6 people
- Sponsor
- SWOG Cancer Research Network
Bladder Cancer, Bladder Neoplasm
Preoperative Physical Activity Improvement With the Use of Activity Trackers Before Radical Cystectomy (PreAct)
A bicentric, open-label randomised controlled trial (RCT) is planned to investigate whether the use of fitness wristbands in a defined preoperative period prior to radical cystectomy leads to a preoperative increase in…
- Conditions
- Bladder Cancer, Bladder Neoplasm, Bladder Urothelial Carcinoma
- Trial name
- PreAct (NCT06416319)
- Testing
- Daily Activity Goal and Feedback
- Where
- 2 sites in Germany
- Volunteers
- 164 people
- Sponsor
- Universitätsmedizin Mannheim
Non-muscle-invasive Bladder Cancer
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
This is a randomized, open-label, multi-center, global, phase III study to determine the efficacy and safety of Durvalumab + BCG combination therapy in the treatment of patients with non-muscle-invasive bladder cancer
- Trial name
- POTOMAC (NCT03528694)
- Testing
- Durvalumab (MEDI4736), Bacillus Calmette-Guerin (BCG)
- Where
- 120 sites in Australia, Austria and 10 more
- Volunteers
- 1,018 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.